{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:12:20Z","timestamp":1766869940135,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["121Z691"],"award-info":[{"award-number":["121Z691"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02247-8","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T20:01:33Z","timestamp":1703620893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells"],"prefix":"10.1007","volume":"41","author":[{"given":"Merve","family":"\u015eansa\u00e7ar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helin","family":"Sa\u011f\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-9144","authenticated-orcid":false,"given":"Emel Ba\u015fak","family":"Gencer Ak\u00e7ok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"2247_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jped.2015.08.008","volume":"92","author":"LMC De","year":"2016","unstructured":"De LMC, Da SDB, Freund APF, Dacoregio JS, Costa TEJB, Costa I, et al. Acute myeloid leukemia: analysis of epidemiological profile and survival rate. J Pediatr (Rio J). 2016;92:283\u20139.","journal-title":"J Pediatr (Rio J)"},{"key":"2247_CR2","first-page":"4","volume":"10","author":"M Nix","year":"2019","unstructured":"Nix M, Price A. Acute myeloid leukemia: an ever-changing disease. J Adv Pract Oncol. 2019;10:4\u20138.","journal-title":"J Adv Pract Oncol"},{"key":"2247_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2247_CR4","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia. Cancer. 2013;119:2720\u20137.","journal-title":"Cancer"},{"key":"2247_CR5","first-page":"328","volume":"11","author":"FA Lagunas-Rangel","year":"2017","unstructured":"Lagunas-Rangel FA, Ch\u00e1vez-Valencia V, \u00c1ngel G\u00f3mez-Guijosa M, Cortes-Penagos C. Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res Rev. 2017;11:328.","journal-title":"Int J Hematol Oncol Stem Cell Res Rev"},{"key":"2247_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:441.","journal-title":"Blood Cancer J"},{"key":"2247_CR7","doi-asserted-by":"crossref","unstructured":"Harrison CJ. Targeting signaling pathways in acute lymphoblastic leukemia: new insights. http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/118\/1250024\/bep00113000118.pdf","DOI":"10.1182\/asheducation-2013.1.118"},{"key":"2247_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95:819\u201328.","journal-title":"Haematologica"},{"key":"2247_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a011189","volume":"4","author":"BA Hemmings","year":"2012","unstructured":"Hemmings BA, Restuccia DF. PI3K-PKB\/Akt pathway. Cold Spring Harb Perspect Biol. 2012;4:1.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2247_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","volume":"102","author":"Q Xu","year":"2003","unstructured":"Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003;102:972\u201380.","journal-title":"Blood"},{"key":"2247_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.gastro.2011.05.010","volume":"141","author":"J Zhang","year":"2011","unstructured":"Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011;141:50\u201361.","journal-title":"Gastroenterology"},{"key":"2247_CR12","first-page":"2891","volume":"18","author":"Y Hao","year":"2019","unstructured":"Hao Y, Zhang N, Wei N, Yin H, Zhang Y, Xu H, et al. Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K\/Akt\/mTOR signaling pathway. Oncol Lett. 2019;18:2891\u20136.","journal-title":"Oncol Lett"},{"key":"2247_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1479-5876-9-133","volume":"9","author":"AA Elfiky","year":"2011","unstructured":"Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, et al. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med. 2011;9:133.","journal-title":"J Transl Med"},{"key":"2247_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fonc.2020.00393","volume":"10","author":"C Annageldiyev","year":"2020","unstructured":"Annageldiyev C, Tan SF, Thakur S, Dhanyamraju PK, Ramisetti SR, Bhadauria P, et al. The PI3K\/AKT pathway \u0131nhibitor ISC-4 \u0131nduces apoptosis and \u0131nhibits growth of leukemia in preclinical models of acute myeloid leukemia. Front Oncol. 2020;10:393.","journal-title":"Front Oncol"},{"key":"2247_CR15","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/ijms21082907","volume":"31","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;31:2907.","journal-title":"Int J Mol Sci"},{"key":"2247_CR16","volume":"13","author":"H Zhang","year":"2018","unstructured":"Zhang H, Song G, Song G, Li R, Gao M, Ye L, et al. Identification of DNA methylation prognostic signature of acute myelocytic leukemia. PLoS ONE. 2018;13: 199689.","journal-title":"PLoS ONE"},{"key":"2247_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/leu.2013.264","volume":"28","author":"MV Stankov","year":"2014","unstructured":"Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia. 2014;28:577\u201388.","journal-title":"Leukemia"},{"key":"2247_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19\u201325.","journal-title":"Mol Oncol"},{"key":"2247_CR19","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers11111794","volume":"11","author":"ES Jos\u00e9-En\u00e9riz","year":"2019","unstructured":"Jos\u00e9-En\u00e9riz ES, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers (Basel). 2019;11:1794.","journal-title":"Cancers (Basel)"},{"key":"2247_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6: 026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2247_CR21","doi-asserted-by":"publisher","first-page":"2815187","DOI":"10.1155\/2022\/2815187","volume":"2022","author":"J Chen","year":"2022","unstructured":"Chen J, Cao L, Ma J, Yue C, Zhu D, An R, et al. hdac8 promotes liver metastasis of colorectal cancer via \u0131nhibition of IRF1 and upregulation of SUCNR1. Oxid Med Cell Longev. 2022;2022:2815187.","journal-title":"Oxid Med Cell Longev"},{"key":"2247_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom9120824","volume":"9","author":"CF Chiu","year":"2019","unstructured":"Chiu CF, Chin HK, Huang WJ, Bai LY, Huang HY, Weng JR. Induction of apoptosis and autophagy in breast cancer cells by a novel hdac8 inhibitor. Biomolecules. 2019;9:824.","journal-title":"Biomolecules"},{"key":"2247_CR23","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.7314\/APJCP.2013.14.4.2503","volume":"14","author":"R Sriraks","year":"2013","unstructured":"Sriraks R, Limpaiboon T. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma -cell line findings. Asian Pac J Cancer Prev. 2013;14:2503\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2247_CR24","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"TCS Ho","year":"2020","unstructured":"Ho TCS, Chan AHY, Ganesan A. Thirty years of HDAC \u0131nhibitors: 2020 \u0131nsight and hindsight. J Med Chem. 2020;63:12460\u201384.","journal-title":"J Med Chem"},{"key":"2247_CR25","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-08-1587","volume":"15","author":"K Shiozawa","year":"2009","unstructured":"Shiozawa K, Nakanishi T, Tan M, Fang H, Wang WC, Edelman MJ, et al. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res. 2009;15:1698\u2013707.","journal-title":"Clin Cancer Res"},{"key":"2247_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13016","volume":"167","author":"M Kirschbaum","year":"2014","unstructured":"Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014;167:185\u201393.","journal-title":"Br J Haematol"},{"key":"2247_CR27","first-page":"1797","volume":"54","author":"A Urdiciain","year":"2019","unstructured":"Urdiciain A, Erausquin E, Mel\u00e9ndez B, Rey JA, Idoate MA, Castresana JS. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells. Int J Oncol. 2019;54:1797\u2013808.","journal-title":"Int J Oncol"},{"key":"2247_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.molonc.2015.04.002","volume":"9","author":"KV Woan","year":"2015","unstructured":"Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015;9:1447\u201357.","journal-title":"Mol Oncol"},{"key":"2247_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2020.00844","volume":"8","author":"M Spreafico","year":"2020","unstructured":"Spreafico M, Gruszka AM, Valli D, Mazzola M, Deflorian G, Quint\u00e8 A, et al. HDAC8: a promising therapeutic target for acute myeloid leukemia. Front Cell Dev Biol. 2020;8:1.","journal-title":"Front Cell Dev Biol"},{"key":"2247_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2008.9","volume":"22","author":"S Balasubramanian","year":"2008","unstructured":"Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22:1026\u201334.","journal-title":"Leukemia"},{"key":"2247_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"2247_CR32","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1007\/s11033-022-07560-5","volume":"49","author":"M Yenig\u00fcl","year":"2022","unstructured":"Yenig\u00fcl M, Ak\u00e7ok \u0130, Gencer Ak\u00e7ok EB. Ethacrynic acid and cinnamic acid combination exhibits selective anticancer effects on K562 chronic myeloid leukemia cells. Mol Biol Rep. 2022;49:7521\u201330.","journal-title":"Mol Biol Rep"},{"key":"2247_CR33","doi-asserted-by":"publisher","first-page":"782065","DOI":"10.3389\/fonc.2021.782065","volume":"11","author":"A Huang","year":"2021","unstructured":"Huang A, Zeng P, Li Y, Lu W, Lai Y. LY294002 Is a promising \u0131nhibitor to overcome sorafenib resistance in FLT3-ITD mutant AML cells by \u0131nterfering with PI3K\/Akt signaling pathway. Front Oncol. 2021;11:782065.","journal-title":"Front Oncol"},{"key":"2247_CR34","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00432-015-2064-5","volume":"1659","author":"D Pchejetski","year":"2016","unstructured":"Pchejetski D, Alfraidi A, Sacco K, Alshaker H, Muhammad A, Monzon L. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J Cancer Res Clin Oncol. 2016;1659:1659\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2247_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","volume":"16","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16:1111\u201320.","journal-title":"Expert Opin Investig Drugs"},{"key":"2247_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3390\/cancers14041067","volume":"14","author":"R Chilamakuri","year":"2022","unstructured":"Chilamakuri R, Agarwal S. Dual targeting of PI3K and HDAC by CUDC-907 \u0131nhibits pediatric neuroblastoma growth. Cancers (Basel). 2022;14:1067.","journal-title":"Cancers (Basel)."},{"key":"2247_CR37","doi-asserted-by":"publisher","first-page":"128825","DOI":"10.1016\/j.bmcl.2022.128825","volume":"71","author":"K Zhang","year":"2022","unstructured":"Zhang K, Huang L, Lai F, Lin S, Tian H, Wu D, et al. Bioevaluation of a dual PI3K\/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma. Bioorg Med Chem Lett. 2022;71:128825.","journal-title":"Bioorg Med Chem Lett"},{"key":"2247_CR38","first-page":"431","volume":"4","author":"E Telles","year":"2012","unstructured":"Telles E, Seto E. Modulation of cell cycle regulators by HDACs. Front Biosci. 2012;4:431.","journal-title":"Front Biosci"},{"key":"2247_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/bs.mie.2016.09.053","volume":"1","author":"M Rodr\u00edguez-Arribas","year":"2017","unstructured":"Rodr\u00edguez-Arribas M, Yakhine-Diop SMS, Gonz\u00e1lez-Polo RA, Niso-Santano M, Fuentes JM. Turnover of lipidated LC3 and autophagic cargoes in mammalian cells. Methods Enzymol. 2017;1:55\u201370.","journal-title":"Methods Enzymol"},{"key":"2247_CR40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3324\/haematol.2019.244186","volume":"106","author":"A Wang","year":"2020","unstructured":"Wang A, Chen Hu, Chen C, Liang X, Wang B, Zou F, et al. Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia. Haematologica. 2020;106:605\u20139.","journal-title":"Haematologica"},{"key":"2247_CR41","doi-asserted-by":"publisher","first-page":"21755","DOI":"10.1021\/acsomega.3c01317","volume":"8","author":"M Yenig\u00fcl","year":"2023","unstructured":"Yenig\u00fcl M, Gencer Ak\u00e7ok EB. Histone deacetylase inhibition and autophagy modulation induces a synergistic antiproliferative effect and cell death in cholangiocarcinoma cells. ACS Omega. 2023;8:21755\u201368.","journal-title":"ACS Omega"},{"key":"2247_CR42","first-page":"322","volume":"70","author":"P Chen","year":"2015","unstructured":"Chen P, Wu J, Yuan Q, Jiang X, Huang H. The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K\/Akt signaling pathway inhibitor LY294002. Pharmazie. 2015;70:322\u20137.","journal-title":"Pharmazie"},{"key":"2247_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3892\/or.2021.8048","volume":"45","author":"Y Geng","year":"2021","unstructured":"Geng Y, Wu W, Zhou L, Li J, Geng Y, Yang Y. Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells. Oncol Rep. 2021;45:97.","journal-title":"Oncol Rep"},{"key":"2247_CR44","doi-asserted-by":"crossref","unstructured":"Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, et al. Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers. Cancer Research Communications. 2023;","DOI":"10.1158\/2767-9764.CRC-23-0250"},{"key":"2247_CR45","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3324\/haematol.2019.233445","volume":"106","author":"X Li","year":"2020","unstructured":"Li X, Yongwei Su, Hege K, Madlambayan G, Edwards H, Knight T, et al. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2020;106:1262\u201377.","journal-title":"Haematologica"},{"key":"2247_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115283","volume":"205","author":"K Hege Hurrish","year":"2022","unstructured":"Hege Hurrish K, Qiao X, Li X, Su Y, Carter J, Ma J, et al. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia. Biochem Pharmacol. 2022;205: 115283.","journal-title":"Biochem Pharmacol"},{"key":"2247_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","volume":"17","author":"J Qi","year":"2015","unstructured":"Qi J, Singh S, Hua WK, Cai Q, Chao SW, Li L, et al. HDAC8 \u0131nhibition specifically targets \u0131nv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. Cell Stem Cell. 2015;17:597\u2013610.","journal-title":"Cell Stem Cell"},{"key":"2247_CR48","first-page":"2883","volume":"34","author":"P Quan","year":"2014","unstructured":"Quan P, Mo\u0131nfar F, Kufferath I, Absenger M, Kuezn\u0131k T, Denk H, et al. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K\/AKT\/mTOR signaling. Anticancer Res. 2014;34:2883.","journal-title":"Anticancer Res"},{"key":"2247_CR49","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s43587-021-00098-4","volume":"1","author":"Y Aman","year":"2021","unstructured":"Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, et al. Autophagy in healthy aging and disease. Nat Aging. 2021;1:634\u201350.","journal-title":"Nat Aging."},{"key":"2247_CR50","doi-asserted-by":"publisher","first-page":"e0137675","DOI":"10.1371\/journal.pone.0137675","volume":"10","author":"MI Koukourakis","year":"2015","unstructured":"Koukourakis MI, Kalamida D, Giatromanolaki A, Zois CE, Sivridis E, Pouliliou S, et al. Autophagosome proteins LC3A, LC3B and LC3C have distinct subcellular distribution kinetics and expression in cancer cell lines. PLoS ONE. 2015;10:e0137675.","journal-title":"PLoS ONE"},{"key":"2247_CR51","first-page":"7233","volume":"61","author":"SP Whitman","year":"2001","unstructured":"Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233\u20139.","journal-title":"Cancer Res"},{"key":"2247_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6:1.","journal-title":"Oncol Rev"},{"key":"2247_CR53","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood.2019003538","volume":"135","author":"J Long","year":"2020","unstructured":"Long J, Jia M-Y, Fang W-Y, Chen X-J, Mu L-L, Wang Z-Y, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020;135:1472\u201383.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02247-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:19:32Z","timestamp":1704709172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02247-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["2247"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02247-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"31"}}